Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.58 |
| ▸ | PLAU | P00749 | 3/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619591 | 1.00 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CPLAUGBA1 | |
| SCHEMBL31600623 | 1.00 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CPLAUGBA1 | |
| SCHEMBL17221502 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL17221501 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL16795113 | 0.76 | MEN1 (0.34) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL18128809 | 0.76 | MEN1 (0.34) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL1354526 | 0.75 | NOS3 (0.39) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL1354527 | 0.75 | NOS3 (0.39) | ADRA2AADRA2BADRA2CPLAUKDM4E | |
| SCHEMBL16792283 | 0.73 | — | — | |
| SCHEMBL18339066 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598163-B2 | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders | VITAE PHARMACEUTICALS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2393813-B1 | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol | VITAE PHARMACEUTICALS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | HSD11B1, HSD11B2, HSD17B1 | ADRA2A 1138/4885ADRA2B 951/4885ADRA2C 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.